Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis. Today, our panel of experts will explore the treatment landscape and impact of multiple sclerosis ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Multiple Sclerosis Market and Competitive Landscape Highlights - 2016" report to their offering. The latest ...

Signs of multiple sclerosis may surface years before diagnosis, as patients use healthcare more often for early symptoms.

Scientists have long suspected that industrial pollutants might help trigger multiple sclerosis, but the latest evidence ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.

Multiple sclerosis (MS) is a chronic, disabling, inflammatory disease that damages your nerves. People with MS may live roughly seven years less than the general population, with an average life ...

DelveInsight's“ Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the ...